Identifying Milestones for Treatment Success
Key RESTASIS® Treatment Success Milestones
| 1 Month | 3 Months | 6 Months | >6 Months |
|---|---|---|---|
|
Noticeable increase in tear production May need to use artificial tears for temporary relief |
Further increase in tear production Use of artificial tears may be reduced Patient follow-up visit with doctor to measure progress |
Peak increase in tear production Use of artificial tears may be reduced
|
Peak increase in tear production maintained with continued therapy Use of artificial tears may be reduced
|
Depending on the patient’s condition, the effects of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% may be noticeable within 1 month.
Dr. Stephen Reed discusses milestones and his personal experience with RESTASIS®.
Patients using RESTASIS® Ophthalmic Emulsion may first notice they are using artificial tears less and less. Over the course of time, with RESTASIS® achieving its full effect on a patient’s natural ability to produce tears, patients may be able to further reduce use of artificial tears.
It is reasonable for many patients to expect a sustained increase in tear production with continued use of RESTASIS® Ophthalmic Emulsion, which can lead to a reduction in artificial tear usage. And in most patients, this kind of efficacy is sustained with just 1 drop of RESTASIS® in each eye, twice a day, 12 hours apart.
But it’s also important for you to remind them that there is no permanent cure. It will be necessary for patients to continue using RESTASIS® Ophthalmic Emulsion twice a day, every day, even after tear production has been increased.
Click here to locate and download a simple educational piece that offers your patients “quick tips” on what to expect from RESTASIS® therapy.
© 2007 Allergan, Inc. All rights reserved | Privacy Statement | FAQs | Terms of Use | Site Map
This information is intended for residents of the United States. ® and ™ marks owned by Allergan, Inc.
RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
Important Safety Information:
RESTASIS® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.
The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Please see full prescribing information for RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%.